FDA OKs Roche's HPV test as first-line cervical cancer screen
This article was originally published in Clinica
Executive Summary
The US FDA has approved Roche Molecular Diagnostics’ cobas human papillomavirus DNA as a first-line primary screening tool for cervical cancer in women 25 and older, giving the firm a potential leg up in the competitive HPV assay space.